The Technical Analyst
Select Language :
PDS Biotechnology Corp [PDSB]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

PDS Biotechnology Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

PDS Biotechnology Corp is listed at the  Exchange

2.86% $3.96

America/New_York / 28 mar 2024 @ 16:00


PDS Biotechnology Corp: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 123.19 mill
EPS: -1.710
P/E: -2.32
Earnings Date: May 13, 2024
SharesOutstanding: 31.11 mill
Avg Daily Volume: 0.855 mill
RATING 2024-03-28
A-
Buy
RATINGS
Rating CashFlow: Neutral
Return On Equity: Neutral
Return On Asset: Buy
DE: Sell
P/E: Strong Buy
Price To Book: Neutral
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/a
Ebit
Asset n/a
Debtn/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.32 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.39x
Company: PE -2.32 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$1.760
(-55.54%) $-2.20
Date: 2024-03-28
Expected Trading Range (DAY)

$ 3.54 - 4.38

( +/- 10.66%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-01-22 Shepard Kirk V. Buy 200 000 Employee Stock Option (Right to Buy)
2024-01-22 Shepard Kirk V. Buy 0
2023-12-04 Boesgaard Lars Buy 200 000 Employee Stock Option (Right to Buy)
2023-12-04 Boesgaard Lars Buy 0
2023-07-14 Freitag Gregory Gene Buy 9 000 Employee Stock Option (Right to Buy)
INSIDER POWER
70.77
Last 91 transactions
Buy: 4 791 106 | Sell: 920 084

Forecast: 16:00 - $3.96

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $3.96
Forecast 2: 16:00 - $3.96
Forecast 3: 16:00 - $3.96
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $3.96 (2.86% )
Volume 2.27 mill
Avg. Vol. 0.855 mill
% of Avg. Vol 266.04 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for PDS Biotechnology Corp

Last 12 Months

Last 12 months chart data with high, low, open and close for PDS Biotechnology Corp

RSI

Intraday RSI14 chart for PDS Biotechnology Corp

Last 10 Buy & Sell Signals For PDSB

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$5.31N/AActive
Profile picture for
            PDS Biotechnology Corp

PDSB

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Last 10 Buy Signals

Date Signal @
SNXUSDMar 28 - 20:05$5.02
GLMRUSDMar 28 - 20:030.508
XAUTUSDMar 28 - 20:02$2 229.60
SBDUSDMar 28 - 20:02$4.77
GTCUSDMar 28 - 20:032.15
ETHWUSDMar 28 - 20:034.34
SEIUSDMar 28 - 20:020.862
STORJUSDMar 28 - 20:02$0.829
GALAUSDMar 28 - 20:02$0.0676
KNCUSDMar 28 - 20:02$0.911

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.